In the May issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium on the association between prophylactic gabapentin, weight loss, and narcotic dependency in patients with oropharyngeal cancer undergoing radiation therapy. The authors of the study found that prophylactic gabapentin 300 mg 3 times daily diminished narcotic dependency and weight loss in patients with head and neck cancer. We also highlight notable studies that were presented at the 2016 Genitourinary Cancers Symposium and 2016 Cancer Survivorship Symposium, and bring you news from the 12th Hematology/Oncology Pharmacy Association Annual Conference.
In addition to coverage from recent conferences, we provide valuable insight on using advances in technology to facilitate communication with cancer survivors, US Food and Drug Administration news updates, and ways to save taxes while you invest.
In this issue’s reader poll, we ask you whether your institution or practice has methods in place for identifying and addressing symptoms causing distress in your patients with acute myeloid leukemia. Please visit our website, www.TheOncologyPharmacist.com, to share with us your response. You can also send comments to info@TheOncologyPharmacist.com. We hope you will enjoy this issue, and look forward to your feedback.
